Home/Pipeline/AV-GBM-1

AV-GBM-1

Glioblastoma

Phase 2/3Active

Key Facts

Indication

Glioblastoma

Phase

Phase 2/3

Status

Active

Company

AIVITA Biomedical

About AIVITA Biomedical

AIVITA Biomedical is a private, clinical-stage biotech leveraging its proprietary stem cell and autologous immunotherapy platform to develop personalized vaccines. Its lead oncology programs target glioblastoma and melanoma, with a Phase 2/3 trial planned for glioblastoma and a Phase 1B trial ongoing in melanoma. The company has also developed a multi-pathogen vaccine kit and funds its R&D in part through a clinically validated skincare product line.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other Glioblastoma Drugs

Drug	Company	Phase	Status
Ropidoxuridine (IPdR)	Shuttle Pharmaceuticals	Phase 2	Active
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
Glioblastoma Moonshot	Owkin	Research	Open Project
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
αvβ3-targeted ADC	Xintela	Preclinical	Lead Optimization
Undisclosed	Biossil	Phase 2/3	Active
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
LMP744	Gibson Oncology	Phase 2	Active